Poseida raises $30.5M series B

Gene editing company Poseida Therapeutics Inc. (San Diego, Calif.) raised $30.5 million in an oversubscribed, untranched series B round led by new investor Longitude Capital. New investors Vivo Capital and the Tavistock Group also participated alongside existing investor Malin Corp. plc (ISE:MLC).

A Poseida spokesperson told BioCentury that data from a Phase I trial of the company's lead candidate, P-BCMA-101, to treat multiple myeloma could be reported next half. P-BCMA-101 comprises CAR T cells targeting tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)...